Developmental Hep C Drug Gets Good Initial Marks
Share
Follow Us
Idera Pharmaceuticals reports positive antiviral results from phase 1 study for Hep C drug
Monday, December 20, 2010
Idera Pharmaceuticals (Nasdaq: IDRA) announced Monday positive preliminary results from a phase 1 study for IMO-2125, the company’s investigational drug treatment for chronic hepatitis C infection.
Hep C is an infectious disease affecting the liver. It is often asymptomatic, but once established, chronic infection can progress to scarring of the liver. In some cases, people will go on to develop liver failure or other complications, including liver cancer.
During the 4-week dose-ranging trial, the IMO-2125 drug was tested in combination with ribavirin, in 60 patients with the virus. The results indicated a “substantial decline” in virus levels at two days after the first dose of IMO-2125, and after four weeks of treatment, the company said.
Continue reading this entire article:
http://www.proactiveinvestors.com/companies/news/10985/idera-pharmaceuticals-reports-positive-antiviral-results-from-phase-1-study-for-hep-c-drug-10985.html
